Related Experiment Videos
Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects
D Journois1, P Pouard, P Mauriat
1Department of Anesthesia and Intensive Care Medicine, Hôpital Laennec, Paris, France.
Insights
Inhaled nitric oxide effectively treated pulmonary artery hypertension in infants after heart surgery when other methods failed. This therapy selectively dilated pulmonary arteries, improving oxygen saturation and hemodynamics with minimal systemic effects.
Area of Science:
- Pediatric Cardiology
- Neonatal Intensive Care
- Cardiovascular Pharmacology
Background:
- Pulmonary artery hypertension (PAH) is a critical complication in infants following congenital heart defect (CHD) surgery.
- Conventional medical therapies often fail to manage severe PAH in this vulnerable population.
- Effective management of PAH is crucial for improving outcomes in neonates undergoing cardiac repair.
Purpose of the Study:
- To evaluate the efficacy and safety of inhaled nitric oxide (iNO) in infants with critical PAH post-CHD surgery.
- To assess the impact of iNO on pulmonary artery pressures and systemic hemodynamics.
- To determine if iNO offers a viable treatment option after conventional therapies have failed.
Main Methods:
- Seventeen infants with critical PAH post-CHD surgery were treated with 20 ppm of inhaled nitric oxide.
- Patients had failed conventional medical therapy including hyperventilation, sedation, and acidosis correction.
- Hemodynamic parameters, including pulmonary artery pressure and oxygen saturation, were monitored via pulmonary artery catheter.
Main Results:
- Inhaled nitric oxide significantly decreased mean pulmonary arterial pressure by 34% +/- 21%.
- Systemic arterial pressure remained stable, while arterial and venous oxygen saturation improved.
- Fifteen of seventeen infants were discharged from the ICU, indicating a favorable short-term outcome.
Conclusions:
- Inhaled nitric oxide provides selective pulmonary vasodilation in infants with CHD-associated PAH.
- This therapy improves oxygenation and overall hemodynamics without compromising systemic blood pressure.
- Careful risk-benefit assessment is necessary due to potential toxic effects of nitric oxide and nitrogen dioxide.
Abstract:
Seventeen infants were treated with inhaled nitric oxide for critical pulmonary artery hypertension after operations for congenital heart defects. In all 17 patients conventional medical therapy consisting of hyperventilation, deep sedation/analgesia, and correction of metabolic acidosis had failed. All children were monitored with a transthoracic pulmonary artery catheter inserted at operation. Pulmonary artery hypertension was defined as an acute rise in pulmonary pressure associated with a decrease in oxygen arterial or venous saturation. After failure of conventional medical therapy, 20 ppm of inhaled nitric oxide was administered to the patient. In all patients the pulmonary pressures decreased (mean pulmonary arterial pressure decreased by -34% +/- 21%) without significant change in systemic arterial pressure, whereas the oxygen arterial saturation and oxygen venous saturation increased by 9.7% +/- 12% and 37% +/- 28%, respectively. Fifteen children were discharged from the intensive care unit at 10 +/- 6 days (range 3 to 26 days) and two died. This study demonstrates that inhaled nitric oxide exerts a selective pulmonary vasodilation without decreasing systemic arterial pressure in children with congenital heart disease. The increased values of mixed venous oxygen saturation and urinary output suggest that this selective lowering of pulmonary vascular resistance improved the overall hemodynamics. The potential toxic effects of nitric oxide and nitrogen dioxide necessitate careful consideration of the risks and benefits of inhaled nitric oxide therapy.